Quick theoretical question...Solid tumours have long been an issue when it comes to CAR-T capabilities. I understand the use of cf33 to induce CD19 expression on solid tumour cell lines then further treating with CD19 targeting therapies. However in melanoma for example, HER2-CAR T targetting cells have very limited effect against HER2+ Tu in murine. A lot of people have put this down to matter of a more difficult and intricate tumour microenvironment? So does that mean cf33 just induces an extreme expression of target antigen (cd19) and this how it can get an upperhand on a cell line that may express 100% but not at this extreme amount? TIA, GLTA
- Forums
- ASX - By Stock
- Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
Quick theoretical question...Solid tumours have long been an...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $418.9M |
Open | High | Low | Value | Volume |
5.6¢ | 5.7¢ | 5.4¢ | $461.9K | 8.347M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1082545 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 603058 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 341818 | 0.055 |
9 | 509187 | 0.054 |
14 | 1776123 | 0.053 |
22 | 1646348 | 0.052 |
16 | 4794350 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 603058 | 6 |
0.058 | 1006279 | 6 |
0.059 | 21714 | 1 |
0.060 | 1512398 | 12 |
0.061 | 1091000 | 7 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |